Rivaroxaban Plus Aspirin Versus Aspirin Alone After En Symptomatic PAD: Insights From VOYAGER PAD

Circulation

148, 1919-1928

DOI: 10.1161/circulationaha.122.063806

Citation Report

#	Article	IF	Citations
1	Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease. Circulation, 2023, 148, 1929-1931.	24.6	1
2	Drug-Coated Balloons With or Without Provisional Bare Metal Stenting in Femoropopliteal Disease: No Metal Left Behind?. Circulation: Cardiovascular Interventions, 2024, 17, e013847.	6.2	1
3	Einsatz von Rivaroxaban nach Revaskularisierung bei symptomatischer paVK. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2024, 11, 30-30.	0.0	0
4	Clinical Outcomes of Non–Stent-Based Interventions for Symptomatic Below-the-Knee Peripheral Artery Disease in the Excellence in Peripheral Artery Disease (XLPAD) Registry. American Journal of Cardiology, 2024, 228, 38-47.	2.4	5
5	One-Year Clinical Outcomes of Endovascular Revascularization in Patients With Acute Limb Ischemia. Heart and Vessels, 2025, 40, 1-8.	1.8	3
6	Addressing Common Inferential Mistakes When Failing to Reject the Null-Hypothesis. F1000Research, 2024, 13, 1488.	1.1	4
7	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7
8	Quercetin Ameliorates Ox-LDL-Induced Cellular Senescence of Aortic Endothelial Cells and Macrophages by p16/p21, p53/SERPINE1, and AMPK/mTOR Pathways. European Journal of Medical Research, 2025, 30, 359.	5.0	31
9	Antithrombotic Treatment Following Revascularization for Chronic Limb-Threatening Ischaemia: A Scientific Statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2025, 46, 2742-2759.	14.7	6
10	Oral Anticoagulant Management for Peripheral Vascular Disease. Advances in Surgery, 2025, 59, 161-199.	2.1	0
11	Late Outcomes of Viabahn Self-Expandable Covered Stents for the Elective Treatment of Popliteal Artery Aneurysms. Journal of Vascular Surgery, 2025, 82, 1658-1668.	3.4	7
12	DGK-Kommentar zu den Leitlinien der ESC (2024) zur Behandlung der peripheren arteriellen und aortalen Erkrankungen. Die Kardiologie, 2025, 19, 366-378.	1.4	0
13	Neuronal Endothelin a Receptor Mediates Experimental and Clinical Vascular Pain Through an Endothelial-Neural Axis. Advanced Science, 2025, 12, e12375.	12.7	10
14	MicroRNA-223-3p Is a Determinant of Platelet Procoagulant Activity. Blood Advances, 2026, 10, 83-94.	6.3	5
15	Endothelial CEPT1 Promotes Angiogenesis Through PPARα and VEGF-A Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2026, 46, 195-209.	7.9	3
16	Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions, 2026, 19, e015229.	6.2	1
17	Peripheral Artery Disease Treatment: Scoping Review With ❄SAIMSARA. , 2026, .		0
18	Current and Emerging Approaches to Managing Peripheral Artery Disease: A Specialist Review. Heart, 2026, .	4.9	3

#	Article	IF	Citations
19	Management of Recurrent Venous Thromboembolism on Anticoagulation. Journal of Clinical Medicine, 2026, 15, 3415.	3.8	0
20	Peripheral Artery Disease and Amputation: Scoping Review With ❁SAIMSARA. , 2026, .		0
21	Efficacy and Safety of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Annals of Medicine and Surgery, 2026, 88, 4437-4447.	1.7	0
22	PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction. Medicina (Lithuania), 2026, 62, 1905.	3.3	0